NCT06824987: APPRECIATE

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Recruiting now Phase 2 Last updated 29 October 2025

What this trial tests

Phase 2 trial testing AZD2373-Arm 1 in APOL1-Mediated Kidney Disease in 96 participants. Currently enrolling.

Timeline

5 March 2025

Primary endpoint
30 August 2027

30 August 2027

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	96
Start date	5 March 2025
Primary completion	30 August 2027
Estimated completion	30 August 2027
Sites	77 locations across United Kingdom, United States

Drugs / interventions tested

• AZD2373-Arm 1
• AZD2373-Arm 2
• Placebo
• APOL1 Genotyping Clinical Trial Assay

Conditions studied

• APOL1-Mediated Kidney Disease — all drugs for APOL1-Mediated Kidney Disease →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 65, any sex, with APOL1-Mediated Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years.
   Adebayo OC, Okpoli HC, Vriens J, Levtchenko E, et al · · 2025 · cited 1× · PMID 41402748 · DOI 10.1186/s12882-025-04687-y
2. Apolipoprotein L1 genetic testing, family history of hypertension, and kidney disease in a Midwestern U.S. cohort
   Lentine K, Elsurer Afsar R, Clair B, Memon A, et al ·
3. Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers.
   Xu L, Zhang H, Jiang B, Jiang Y, et al · · 2026 · PMID 42076098 · DOI 10.3390/pharmaceutics18040446
4. Framework for Apolipoprotein 1-Mediated Kidney Disease Classification.
   Wilson JD, Caza TN, Haun RS, Larsen CP. · · 2026 · PMID 41907821 · DOI 10.1016/j.ekir.2026.106408
5. Molecular Mechanisms of APOL1-Associated Kidney Disease.
   Delrue C, Speeckaert R, Speeckaert MM. · · 2026 · PMID 41898722 · DOI 10.3390/ijms27062863